Sarepta Therapeutics Inc (SRPT)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$22.87
Buy
$23.18
$1.10 (+4.97%)
Prices updated at 03 Apr 2026, 00:56 EDT
| Prices minimum 15 mins delay
Prices in USD
Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2024 | 2025 |
|---|---|---|
| 1,902m | 2,198m | |
| 1,583m | 1,359m | |
| 218m | -658m | |
| 11.47 | -29.92 | |
| 235m | -713m | |
| 317m | -620m | |
| Sales, General and administrative | 558m | 492m |
| Interest expenses | 18m | 38m |
| Provision for income taxes | 26m | 11m |
| Operating expenses | 1,365m | 2,016m |
| Income before taxes | 261m | -702m |
| Net income available to common shareholders | 235m | -713m |
| 2.34 | -7.13 | |
| Net interest income | 53m | -1m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | 2.34 | -7.13 |
| Free cash flow per share | -4.7744 | -3.51 |
| Book value/share | 12.6013 | 12.5769 |
| Debt equity ratio | 0.870302 | 0.901571 |
Balance sheet
Year | 2024 | 2025 |
|---|---|---|
| Current assets | 3,073m | 2,538m |
| Current liabilities | 732m | 1,095m |
| Total capital | 2,665m | 1,970m |
| Total debt | 1,343m | 1,040m |
| Total equity | 1,528m | 1,141m |
| Total non current liabilities | - | - |
| Loans | 1,137m | 829m |
| Total assets | 3,963m | 3,350m |
| Total liabilities | - | - |
| Cash and cash equivalents | 1,103m | 801m |
| Common stock | 97m | 105m |
Cash flow
Year | 2024 | 2025 |
|---|---|---|
| Cash at beginning of period | 444m | 1,119m |
| Cash dividends paid | - | - |
| -353m | -315m | |
| Investments (gains) losses | 756m | 70m |
| 1,119m | 814m | |
| Net income | - | - |
| -206m | -205m | |
| -147m | -110m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
